Furthermore, targeting the thioredoxin reductase (Trx) system with butaselen (an organoselenium-containing compound) promotes NK and T cell activity in the TME, inhibiting the immune escape of HCC cells and enhancing the efficacy of PD-1 blockade (208). Here, PRDX5 is linked to hepatocellular carcinoma.